Compare Mesoblast Limited (MESO) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Southern Copper Corp — how do they compare? Mesoblast Limited trades at $16.91 (market cap $2.21B), while Southern Copper Corp trades at $195.51 (market cap $164.21B). The key difference: Southern Copper Corp is far larger — about 74.3× Mesoblast Limited's market cap, and Southern Copper Corp pays a 2.26% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | SCCO | |
|---|---|---|
Market Cap | $2.21B | $164.21B |
Sector | Technology | Basic Materials |
52-Week High | $20.96 | $218.85 |
52-Week Low | $12.88 | $93.70 |
Enterprise Value | $2.21B | $165.50B |
Dividend Yield | — | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.
The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.
SCCO trades at $200.11, up 0.53% today, near its pivot point of $201. The stock exhibits strong profitability with a 35.87% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights its rally fueled by strong H1 results and higher copper prices, though production declines and premium valuations are noted concerns (Zacks Investment Research, 2026-08-11).
Outlook is mixed; robust earnings growth and AI-driven copper demand present upside, but high valuation ratios and analyst skepticism pose risks. The consensus price target of $153.64 suggests significant downside from current levels, indicating caution is warranted despite positive technical and fundamental trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
